Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

The two products accounted for about 48% of Eli Lilly's most recent quarterly sales and drove most of the top-line growth.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound ... by their 11.5% and 16% stock price drop, respectively ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study.